DAT antagonists(Dopamine transporter antagonists), PET imaging(Positron-emission tomography enhancers), SPECT(Single-photon emission-computed tomography enhancers)

Therapeutic Areas

Nervous System DiseasesEndocrinology and Metabolic Disease

Active Indication

Parkinson Disease

Inactive Indication

Attention Deficit Disorder With HyperactivityDementiaTremor

Originator Organization

Harvard University

Active Organization

Harvard University

Alseres Pharmaceuticals, Inc.

Inactive Organization

Navidea Biopharmaceuticals, Inc.

Drug Highest PhasePhase 3

First Approval Date-

Regulation-

Structure

Molecular FormulaC18H21FINO2

InChIKeyGTQLIPQFXVKRKJ-UNSMHXHVSA-N

CAS Registry180468-34-2

Clinical Trials associated with Altropane

NCT05636852 / RecruitingPhase 2

An Open-label Multicenter Phase 2 Dose-evaluation Study of Altropane (123I) Injection for Striatal Dopamine Transporter Visualization Using SPECT Brain Imaging

Previous studies showed that a dose of 8 millicuries of Altropane was appropriate for imaging patients with suspected Parkinson's disease. This study will determine if a lower dose (5 millicuries) would suffice.

Start Date24 Apr 2023

Sponsor / Collaborator

GE Healthcare Holdings, Inc.

[+1]

NCT01950468 / WithdrawnPhase 3

Evaluation of the Diagnostic Efficacy and Safety of [123I]NAV5001 as an Imaging Agent to Aid in the Diagnosis of Parkinsonian Syndromes

This is a phase 3, open-label, multiple-center, randomized cross-over study to assess the safety and efficacy of [123I]NAV5001 SPECT imaging in aiding in the differentiaion of parkinsonian syndromes from non-parkinsonian tremor.

Start Date01 Apr 2017

Sponsor / Collaborator

Navidea Biopharmaceuticals, Inc.

NCT01950455 / TerminatedPhase 3

Evaluation of the Diagnostic Efficacy and Safety of [123I]NAV5001 as an Imaging Agent to Aid in the Diagnosis of Parkinsonian Syndromes

This is a phase 3, open-label, multiple-center, non-randomized single dose study to assess the safety and efficacy of [123I]NAV5001 SPECT imaging in aiding in the differentiaion of parkinsonian syndromes from non-parkinsonian tremor.

Start Date01 Nov 2013

Sponsor / Collaborator

Navidea Biopharmaceuticals, Inc.

100 Clinical Results associated with Altropane

100 Translational Medicine associated with Altropane

100 Patents (Medical) associated with Altropane

155

Literatures (Medical) associated with Altropane

25 Oct 2024·MEDICINE

A network meta-analysis of different acupuncture therapy in the treatment of poststroke cognitive impairment and dementia

Article

Author: Fu, Kaili ; Zhang, Lunzhong ; Zhang, Xuezheng ; Zhao, Manli ; Wang, Zeying ; Huo, Lei

Background::

Poststroke cognitive impairment and dementia (PSCID) is a major cause of stroke-related morbidities and mortalities. Over the last few years, there has been growing evidence supporting the effectiveness of needle-related treatments in PSCID. Our goal was to rate the included therapies and assess the clinical effectiveness of various needle-related treatments in patients with PSCID.

Methods::

We searched PubMed, Web of Science, Cochrane Library, Embase, China National Knowledge Infrastructure (CNKI), China Science and Technology Journal Database (VIP), Chinese Biomedical Literature Service System (SinoMed), Wanfang, FDA.gov, and ClinicalTrials.gov. A mix of subject terms and free words was used to search the databases. The retrieval period was from the inception date of the database to February, 2023. We included SRs and MAs from acupuncture RCTs of patients with PSCID. The Cochrane Risk Assessment Scale was used to evaluate the risk of bias in the included studies. State 17.0 was used for network meta-analysis in accordance with the Bayesian framework.

Results::

There were 34 studies total of 2690 patients. The cumulative ranking curve (SUCRA) revealed that CT + CFT + EA was the most efficient intervention to improve (Mini-Mental State Examination, MMSE) efficiency, followed by CT + CFT + AP to improve (Montreal Cognitive Assessment, MoCA) efficiency, CT + CFT + ACU for improving (Activities of Daily Living scale, ADL) scores, and CT + CFT + EA to improve clinical efficiency.

Conclusion::

The results show that Different acupuncture methods can improve cognitive function and daily living ability in patients with PSCID. Network meta-analysis revealed that both CT + CFT + ACU and CT + CFT + EA appeared to be more beneficial for daily living activities, while CT + CFT + EA and CT + CFT + AP appeared to be more helpful for cognitive performance in patients with PSCID. Treatments including acupuncture are safer and have a reduced incidence of negative side effects.

01 Aug 2024·Journal of vascular surgery

Midterm outcomes of endovascular repair for abdominal aortic aneurysm using the cuff-first technique to prevent type II endoleaks

Article

Author: Ozawa, Hirotsugu ; Tachihara, Hiromasa ; Shirouzu, Miyo ; Shukuzawa, Kota ; Yamada, Yuta ; Ohki, Takao ; Kasa, Kentaro ; Omori, Makiko ; Nakagawa, Hikaru ; Fukushima, Soichiro

OBJECTIVE:

The aim of this study was to evaluate the initial and midterm outcomes of endovascular aneurysm repair (EVAR) for abdominal aortic aneurysm (AAA) using the cuff-first technique (CFT) to prevent type II endoleak (T2EL).

METHODS:

CFT involves deploying an aortic cuff inside the AAA to cover the ostium of the aortic side branch vessels before deploying the main body. We performed a retrospective review of all patients undergoing EVAR with CFT or side branch embolization (SBE) for AAAs at The Jikei University Hospital between 2016 and 2022. Primary endpoint was the rate of aneurysm sac shrinkage. Secondary endpoints were procedure time, radiation exposure, technical and clinical success rates, occurrence of T2EL, and freedom from reintervention or aneurysm-related death.

RESULTS:

Of 406 patients who underwent EVAR for AAAs, CFT was utilized in 56 (CFT group) and SBE in 35 (SBE group); all 91 patients were included in this study. There were no differences in patient demographics between groups, but there were differences in patency rate of the inferior mesenteric artery and absent intraluminal thrombus. The technical success rate per target vessel in the CFT and SBE group was 97.8% and 91.8%, and the clinical success rate was 91.0% and 100%, respectively. The median procedure time was shorter for CFT than for SBE: CFT, 10 (interquartile range [IQR], 6-14) minutes vs SBE, 25 (IQR, 18.5-45) minutes; P < .05), and median radiation exposure was lower for CFT than for SBE (CFT, 1455 (IQR, 840-2634) mGy vs SBE, 2353 (IQR, 1552-3586) mGy; P < .05). During the median follow-up of 25 months (IQR, 12.5-47 months), sac shrinkage occurred at similar rates in both groups (CFT, 37.5% vs SBE, 40.0%; P = .812), and there were no differences in freedom from reintervention (CFT, 96.2% and 91.4% at 12 and 36 months vs SBE, 100% and 89.5% at 12 and 36 months; log-rank P = .761) and freedom from aneurysm-related death (100% at 36 months in both groups; log-rank P = .440). The odds ratio of CFT vs SBE for sac regression was calculated by adjusting for inferior mesenteric artery patency and absent intraluminal thrombus, resulting in no statistical significance (odds ratio, 1.231; 95% confidence interval, 0.486-3.122).

CONCLUSIONS:

CFT is feasible with a shorter procedure time and lower radiation exposure than SBE and comparable mid-term outcomes, including sac shrinkage rate, compared with SBE. We believe that CFT, if anatomically suitable, is an alternative to SBE for the prevention of T2EL during EVAR.

01 Jun 2024·Physiotherapy

Cognitive Functional Therapy compared with usual physiotherapy care in people with persistent low back pain: a mixed methods feasibility randomised controlled trial in the United Kingdom National Health Service

Article

Author: Purtill, Helen ; Singh, Gurpreet ; Newton, Christopher ; Logan, Pip ; Nolan, David ; O'Sullivan, Kieran ; O'Sullivan, Peter ; Diver, Claire ; Booth, Vicky ; O'Neill, Seth

OBJECTIVES:

To determine the feasibility of completing a definitive randomised controlled trial (RCT), evaluating the clinical and cost-effectiveness of Cognitive Functional Therapy (CFT) in comparison to usual physiotherapy care (UPC), for people with persistent low back pain (LBP).

DESIGN AND SETTING:

A two-arm parallel feasibility RCT completed in a United Kingdom (UK) Secondary Care National Health Service (NHS) physiotherapy service.

PARTICIPANTS:

Sixty adult participants who reported LBP lasting for more than three months, that was not attributable to a serious (e.g. cancer) or specific (e.g. radiculopathy) underlying cause, were invited to participate. Participants were allocated at random to receive CFT or UPC.

INTERVENTIONS:

Cognitive Functional Therapy and Usual Physiotherapy Care for persistent LBP.

MAIN OUTCOME MEASURES:

The primary outcome was the feasibility of completing a definitive RCT, defined by recruitment of at least 5 participants per month, delivery of CFT per protocol and securing relevant and acceptable outcome measures. Data concerning study processes, resources, management and participant reported outcome measures were collected at baseline, 3, 6 and 12-month follow-up.

RESULTS:

Sixty participants (n = 30 CFT and n = 30 UPC) were recruited with 80% (n = 48), 72% (n = 43) and 53% (n = 32) retained at 3, 6 and 12-month follow-up respectively. NHS physiotherapists were trained to competence and delivered CFT with fidelity. CFT was tolerated by participants with no adverse events. Relevant and clinically important outcome data were collected at all time points (0.4%, 3%, 1% and 0.8% of data was missing from the returned outcome measure booklets at baseline and 3, 6 and 12-month follow-up respectively). The Roland-Morris disability questionnaire was considered the most suitable primary outcome measure with a proposed sample size of 540 participants for a definitive cluster RCT.

CONCLUSION:

It is feasible to conduct a randomised study of CFT in comparison to UPC for NHS patients. A future study should incorporate an internal pilot to address aspects of feasibility further, including participant retention strategies.

CLINICAL TRIAL REGISTRATION NUMBER:

ISRCTN12965286 CONTRIBUTION OF THE PAPER.

News (Medical) associated with Altropane

27 Mar 2006

·www.biospace.com

Boston Life Sciences To Present At The CIBC World Markets Annual Biotechnology And Specialty Pharmaceuticals Conference

HOPKINTON, Mass., March 28 /PRNewswire-FirstCall/ -- Boston Life Sciences, Inc. today announced that Kenneth L. Rice, Jr., Chief Financial Officer of Boston Life Sciences, Inc., will be presenting a Company update at the CIBC World Markets Annual Biotechnology and Specialty Pharmaceuticals Conference on Tuesday, April 4 at 9:00am EST. The conference is being held April 4 - 5, 2006 at the Millennium Broadway in New York City. The Boston Life Sciences presentation will be available by webcast. Access to the webcast will be available for 90 days following the presentation within the Investor Relations section of the Boston Life Sciences website at . About Boston Life Sciences, Inc. Boston Life Sciences, Inc. (BLSI) is engaged in the research and clinical development of diagnostic and therapeutic products for central nervous system (CNS) disorders. ALTROPANE(R) molecular imaging agent is in Phase III clinical trials for the diagnosis of Parkinsonian Syndrome (PS) and a Phase II clinical trial for the diagnosis of Attention Deficit Hyperactivity Disorder (ADHD). The Company's research and pre-clinical CNS programs include Inosine for the treatment of stroke, a DAT blocker for the treatment of Parkinson's disease and a second generation technetium-based molecular imaging agent for PS and ADHD. BLSI's current research collaborations include Harvard Medical School and Children's Hospital of Boston. ALTROPANE is a registered trademark of Boston Life Sciences, Inc. The foregoing release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward- looking statements include statements regarding Boston Life Sciences' expectations, beliefs, intentions or strategies regarding the future, including the Company's development efforts regarding the Company's ALTROPANE program and the Company's pre-clinical candidates. Forward-looking statements can be identified by terminology such as "anticipate," "believe," "could," "could increase the likelihood," "estimate," "expect," "intend," "is planned," "may," "should," "will," "will enable," "would be expected," "look forward," "may provide," "would" or similar terms, variations of such terms or the negative of those terms. Such forward-looking statements involve known and unknown risks, uncertainties and other factors including those risks, uncertainties and factors referred to in the Company's Quarterly Report on form 10-Q for the quarter ended September 30, 2005, filed with the Securities and Exchange Commission under the section "Risk Factors," as well as other documents that may be filed by Boston Life Sciences from time to time with the Securities and Exchange Commission. As a result of such risks, uncertainties and factors, the Company's actual results may differ materially from any future results, performance or achievements discussed in or implied by the forward-looking statements contained herein. Boston Life Sciences, Inc. is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise. Contact: Sharon Correia -- 508-497-2360 ext 224 Boston Life Sciences, Inc. scorreia@bostonlifesciences.com Boston Life Sciences, Inc. CONTACT: Sharon Correia of Boston Life Sciences, Inc., +1-508-497-2360ext. 224, scorreia@bostonlifesciences.com Web site:

Collaborate

100 Deals associated with Altropane

External Link

KEGG	Wiki	ATC	Drug Bank
-	Altropane	-	DB04947

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Parkinson Disease	Phase 3	US	Navidea Biopharmaceuticals, Inc.	01 Nov 2013
Parkinsonian Disorders	Phase 3	US	Alseres Pharmaceuticals, Inc.	01 Jul 2010
Tremor	Phase 3	US	Alseres Pharmaceuticals, Inc.	01 Jul 2010
Dementia	Phase 2	US	Alseres Pharmaceuticals, Inc.	19 Oct 2013
Attention Deficit Disorder With Hyperactivity	Phase 2	US	Alseres Pharmaceuticals, Inc.	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis